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Objective. This study sought to compare two strategies of
revascularization in patients obtaining a good immediate angio-
graphic result after percutaneous transluminal coronary angio-
plasty (PTCA): elective stenting versus optimal PTCA. A good
immediate angiographic result with provisional stenting was
considered to occur only if early loss in minimal luminal diameter
(MLD) was documented at 30 min post-PTCA angiography.
Background. Coronary stenting reduces restenosis in lesions
exhibiting early deterioration (>0.3 mm) in MLD within the first
24 hours (early loss) after successful PTCA. Lesions with no early
loss after PTCA have a low restenosis rate.
Methods. To compare angiographic restenosis and target vessel
revascularization (TVR) of lesions treated with coronary stenting
versus those treated with optimal PTCA, 116 patients were
randomized to stent (n 5 57) or to optimal PTCA (n 5 59). After
randomization in the PTCA group, 13.5% of the patients crossed
over to stent due to early loss (provisional stenting).
Results. Baseline demographic and angiographic characteris-
tics were similar in both groups of patients. At 7.6 months, 96.6%
of the entire population had a follow-up angiographic study:
98.2% in the stent and 94.9% in the PTCA group. Immediate and
follow-up angiographic data showed that acute gain was signifi-
cantly higher in the stent than in the PTCA group (1.95 vs.
1.5 mm; p < 0.03). However, late loss was significantly higher in
the stent than the PTCA group (0.63 6 0.59 vs. 0.26 6 0.44,
respectively; p 5 0.01). Hence, net gain with both techniques was
similar (1.32 6 0.3 vs. 1.24 6 0.29 mm for the stent and the PTCA
groups, respectively; p 5 NS). Angiographic restenosis rate at
follow-up (19.2% in stent vs. 16.4% in PTCA; p 5 NS) and TVR
(17.5% in stent vs. 13.5% in PTCA; p 5 NS) were similar.
Furthermore, event-free survival was 80.8% in the stent versus
83.1% in the PTCA group (p 5 NS). Overall costs (hospital and
follow-up) were US $591,740 in the stent versus US $398,480 in the
PTCA group (p < 0.02).
Conclusions. The strategy of PTCA with delay angiogram and
provisional stent if early loss occurs had similar restenosis rate
and TVR, but lower cost than primary stenting after PTCA.
(J Am Coll Cardiol 1998;32:1351–7)
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An increasing number of devices used to enhance the results of
percutaneous transluminal coronary angioplasty (PTCA) have
resulted in a remarkable growth in the number of percutane-
ous transluminal coronary revascularization procedures. How-
ever, coronary restenosis after percutaneous coronary inter-
ventions remains the major limitation of these techniques.
Several factors, such as elastic wall recoil, thrombus formation,
smooth muscle cell proliferation and vascular remodeling, are
involved in the process of restenosis (1–4). Recently, two large,
randomized, multicenter trials have demonstrated the efficacy
of coronary stents in reducing angiographic restenosis and
target vessel revascularization (TVR) (5,6).
Although coronary stents are useful in reducing elastic wall
recoil and vascular remodeling, intimal hyperplasia is in-
creased with the use of this device. In fact, late luminal loss is
greater with stents when compared with plain balloon angio-
plasty (5,6). Two major components contribute to the overall
late loss after balloon angioplasty. First, an early component
occurring during the first minutes or hours after the interven-
tional procedure (“early loss”), and second, a late component
(1,7,8). We have previously demonstrated that patients exhib-
iting an early decrease in minimal luminal diameter (MLD) of
.0.3 mm have higher angiographic restenosis rates at
follow-up (1). We have also demonstrated that coronary stents
decrease restenosis rates in this high-risk group of lesions
exhibiting early loss after successful coronary angioplasty (9).
In contrast, lesions with no early loss in MLD after PTCA have
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low angiographic restenosis rates at follow-up (1). The use of
coronary stents in this latter group of lesions with no early loss
in MLD after successful PTCA (optimal PTCA) could be a
subject of controversy. Therefore, the present study was un-
dertaken to determine whether there was any significant
difference in restenosis rate between lesions treated with
primary elective stenting versus those treated with optimal
balloon angioplasty (successful PTCA with delayed angiogram
showing no evidence of early loss at 30 min after successful
PTCA).
Methods
Patient population. The study population consisted of 116
consecutive patients with symptomatic coronary artery disease
undergoing successful PTCA of the novo lesions in native
coronary arteries enrolled in the participating centers of the
Optimal Coronary Balloon Angioplasty With Provisional
Stenting vs. Stent (OCBAS) Trial (a list of the OCBAS centers
appears in the Acknowledgment). Patients were required to
have a successful PTCA with a good immediate angiographic
result before randomization. A good immediate angiographic
PTCA result was defined as residual diameter stenosis #30%,
determined by on-line quantitative coronary angiography
(QCA) and no major dissections visualized in the first angio-
gram of the index artery after the last balloon inflation.
Patients were excluded when they met angiographic or
clinical exclusion criteria. Angiographic exclusions included
lesions .20 mm in length, lesions in coronary artery bypass
grafts (CABGs), vessels with unsuitable anatomy for stenting
(reference diameter ,2.5 mm, diffuse disease, severe left main
stenosis, severe vessel tortuosity) and lesions with acute com-
plications or suboptimal results during PTCA. Patients initially
treated with interventional devices different than balloon an-
gioplasty were also excluded. Clinical exclusions included
contraindications for anticoagulation or antiplatelet therapy,
aspirin or ticlopidine hypersensitivity, noncardiac illness with
less than 1-year life expectancy and previous inclusion in other
randomization protocol. All patients signed a written consent
form approved by the human study committee before the
procedure. The study was carried out according to the princi-
ples of the Declaration of Helsinki and was monitored by a
Safety and Data Monitoring Committee.
Randomization and study protocol. Patients were pre-
treated with aspirin 325 mg/day for at least 24 h before the
procedure. A weight-based intravenous heparin bolus was
given to achieve an activated clotting time greater than 280 s
during the procedure. Ticlopidine 250 mg twice a day orally for
4 weeks was given to patients receiving stents. In addition,
patients in both groups received a calcium channel antagonist
for 3 months. Balloon angioplasty was performed according to
standard technique (10). Stenosis were crossed with a 0.014
high-torque floppy guide wire and dilated with noncompliant
high-pressure balloons using a 1.1:1 balloon-to-artery ratio at a
pressure between 8.0 and 12.0 atm for #60 s. Patients with a
good immediate angiographic result previously enrolled in the
study were randomly assigned to either the stent or the optimal
PTCA groups. Randomization of the patients was carried out
by means of sealed envelopes. A randomization sequence was
developed so that an equal number of patients were assigned
to each treatment strategy at each center.
Patients assigned to the PTCA group had a repeat coronary
angiogram of the index artery 30 min after successful PTCA. If
early loss was demonstrated in the repeat angiogram, patients
crossed over to the stent group (provisional stenting). Early
loss was defined as .0.3 mm loss in MLD and/or .10%
increase in the diameter stenosis severity occurring in repeat
coronary arteriogram performed 30 min after successful
PTCA. All the catheterization laboratories participating in the
study have on-line quantitative coronary angiography.
Patients assigned to the stent group underwent stent im-
plantation immediately after randomization. Stent deployment
and implantation was performed using high-pressure noncom-
pliant balloons at .13 atm of pressure. Intravascular ultra-
sound guidance was not mandatory. Commercially available
stents were used in this trial: they included Gianturco Roubin
II (n 5 33), Palmaz–Schatz (n 5 21), Multilink (n 5 5), Wiktor
(n 5 3), Wallstent (n 5 3) and AVE (n 5 2).
Study end points. The primary end points of the study were
the binary angiographic restenosis and target vessel revascu-
larization at 6-month follow-up. Angiographic restenosis was
defined as $50% of stenosis of the index artery at follow-up
angiography determined by QCA cineangiography.
The secondary end point was a composite end point defined
as event-free survival (freedom from death, myocardial infarc-
tion, angina and need for repeated TVR) at 6-month follow-
up. Death included those deaths from cardiac causes. Myocar-
dial infarction included both Q-wave and non–Q-wave infarcts.
In addition, procedural, hospital and follow-up costs were
included in the comparison of both treatment strategies. The
PTCA and stent costs were estimated according the average
costs for these procedures in Argentina, Chile and Uruguay.
The procedural and hospital estimated cost for a noncompli-
cated PTCA was US $4,500. Additional stent cost was US
$3,000 per stent. These costs include hospital charges, physi-
cian fees and 48-h hospital stay. An additional cost of US $600
was added for each additional day of hospitalization. The costs
for an emergent or elective CABG and for a surgical vascular
repair were US $14,000 and $3,000, respectively. The cost for
CABG included 7 days of hospital stay.
Clinical and angiographic data were forwarded to the Data
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft
MLD 5 minimal luminal diameter
OCBAS 5 Optimal Coronary Balloon Angioplasty with
Provisonal Stenting vs. Stent Trial
PTCA 5 percutaneous transluminal coronary angioplasty
QCA 5 quantitative coronary angiography
TVR 5 target vessel revascularization
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Coordinating Center at the Interventional Cardiovascular Re-
search Center in Buenos Aires for statistical and QCA analysis.
Statistics. The primary analysis of angiographic and clini-
cal outcomes was based on the intentions-to-treat principle.
The results are expressed as mean 6 SD. For comparison of
continuous variables between the two treatment groups, the
unpaired two-tailed Student t test was used. Comparison of
categorical variables between the two groups was performed
using the chi-square method. Comparison of the composite
clinical end point (death, myocardial infarction and repeat
revascularization) was performed using the Kaplan–Meier and
Wilcoxon tests (10). Differences between the groups were
considered to be statistically significant when the p value was
,0.05. Assuming an incidence of restenosis of 40 6 5% for
conventional balloon angioplasty and 20 6 5% for coronary
stenting (5,6) and a decrease in the incidence of restenosis to
20 6 5% for the optimal PTCA group, the power of this pilot
study to detect a difference between both groups of patients
(stent 5 57 vs. optimal PTCA 5 59) with a p ,0.05 was 65%.
Follow-up. Clinical assessment was obtained at 1-, 3- and
6-month follow-up. Coronary angiography was performed at
6-month follow-up in all patients, except those who had died or
had previously undergone a repeat revascularization proce-
dure for any reason during the early follow-up. Although
angiography performed before 3 months of follow-up was
allowed on the basis of clinical indications, a subsequent
angiogram was obtained after 4 months if restenosis was not
documented in the former angiogram.
Quantitative angiographic data. Patients assigned to the
optimal PTCA group were examined angiographically before,
immediately after, at 30 min after and at 6 months after
successful PTCA. Patients assigned to the stent group were
examined angiographically before and immediately after
PTCA, immediately after stenting and at 6 months after stent
placement. For each lesion, the single view showing the most
severe degree of stenosis was used for analysis. Similar single-
view projections were used at each angiographic examination.
The percent degree of coronary stenosis and reference and
minimal diameter were determined using quantitative coro-
nary analysis after the intracoronary administration of 100 mg
of nitroglycerin using an angiographic core laboratory. The
system used was a validated automated edge detection algo-
rithm (11) (Computer Measurements Systems, Medis, the
Netherlands). Absolute reference and MLD in millimeters
were determined using the guiding catheter filled with contrast
for calibration. In additional coronary lesions, morphology was
classified according to the American Heart Association/
American College of Cardiology (AHA/ACC) lesion type
classification utilizing the modification suggested by Ellis et al.
(12).
Results
Patient population. Between December 1995 and July
1996, 953 interventional procedures were performed in the
participating centers in the OCBAS study. From this cohort,
206 consecutive patients treated with balloon angioplasty met
the clinical and angiographic inclusion criteria and were en-
rolled in the study. From those, 86 patients (41.7%) were
excluded due to suboptimal results or acute complications. A
good immediate PTCA result (residual diameter stenosis
#30% determined by on-line QCA and no major dissections
visualized in the first angiogram of the index artery after last
balloon inflation) was obtained in 120 (58.3%) patients. Four
patients refused to participate in the study and 116 were
randomized to stent (n 5 57) or optimal PTCA (n 5 59) and
are the subject of this study.
After randomization, the 57 patients assigned to the stent
group received immediate coronary stenting (group I). The 59
patients assigned to the optimal PTCA group (group II) had a
repeat coronary arteriogram of the index artery 30 min after
PTCA. In this latter group coronary stenting was allowed only
if early loss in MLD was detected in the 30 min post-PTCA
angiogram. There were no significant differences in demo-
graphic, baseline clinical and angiographic characteristics be-
tween the two groups of patients (Table 1).
In-hospital outcome. Stents were successfully deployed in
all patients in the stent group. One patient required multiple
stent placements due to distal dissection. The stents used in
this group of patients included 29 Gianturco Roubin II, 20
Palmaz–Schatz, 3 Wallstents, 3 Wiktors, 2 Multilinks and 2
AVE. Eight patients (13.5%) from the optimal PTCA group
crossed over to stent due to the presence of early loss. In these
eight patients, four Gianturco Roubin II, one Palmaz–Schatz
and three Multilinks stents were successfully deployed. There
were no deaths, emergency CABG, Q-wave myocardial infarc-
tion or abrupt closure in either group. One patient in the stent
group sustained a non–Q-wave myocardial infarction second-
Table 1. Baseline Demographic and Angiographic Characteristics
Stent
(n 5 57)
PTCA
(n 5 59) p
Age (yrs) 58.51 6 11 56.07 6 9 NS
Male/female 49/8 49/11 NS
Unstable angina 45 (78.9%) 48 (81.4%) NS
Stable angina 5 (8.8%) 7 (11.9%) NS
AMI 7 (12.3%) 4 (6.7%) NS
Previous infarction 13 (22.8%) 12 (20.3%) NS
Diabetes mellitus 4 (7%) 8 (13.5%) NS
LAD 35 (61.4%) 22 (37.4%) NS
LCX 11 (19.3%) 23 (38.9%) NS
RCA 11 (19.3%) 14 (23.7%) NS
Lesions data
A 1/57 (1.7%) 1/59 (1.7%) NS
B1 16/57 (28%) 25/59 (42.3%) NS
B2 28/57 (49%) 22/59 (37.3%) NS
C 12/57 (21.3%) 11/59 (18.7%) NS
Total occlusion
(,1 month)
5/57 (8.8%) 10/59 (16.9%) NS
Follow-up angiogram 56/57 (98.2%) 56/59 (95%)
Abbreviations: AMI 5 acute myocardial infarction; LAD 5 left anterior
descending; LCX 5 left circumflex; NS 5 not significant; RCA 5 right coronary
artery.
1353JACC Vol. 32, No. 5 RODRI´GUEZ ET AL
November 1, 1998:1351–7 OPTIMAL PTCA VS. PRIMARY STENTING
ary to a side branch closure. Length of hospital stay was similar
in both the stent and optimal PTCA groups (3.2 6 1 vs. 2.4 6
2 days, respectively).
Angiographic results. The QCA data including reference
and MLD and stenosis for both groups of patients are shown in
Table 2. There were no significant differences in reference
luminal diameter between the stent (3.1 6 0.56 mm) and the
optimal PTCA (2.81 6 0.55 mm) groups (p 5 0.07). Similarly,
there were no significant differences in the pre-PTCA MLD
(0.80 6 0.46 mm vs. 0.70 6 0.46 mm; p 5 0.4 for stent and
optimal PTCA groups, respectively). However, postinterven-
tion MLD in the stent group was significantly larger than the
30 min post-PTCA MLD in the optimal PTCA group (2.7 6
0.59 mm vs. 2.2 6 0.49 mm for the stent and optimal PTCA
groups, respectively; p , 0.0001). The corresponding acute
gain was significantly larger with the stent than with the
optimal PTCA strategy (1.95 vs. 1.5 mm; p 5 0.03). The MLD
at follow-up was similar with stent or PTCA strategy (2.1 6
0.9 mm vs. 1.94 6 0.68 mm for the stent and optimal PTCA
groups, respectively; p 5 NS) (Fig. 1). Late loss was signifi-
cantly greater in the stent than in the optimal PTCA group
(0.63 6 0.59 vs 0.26 6 0.44 mm; p , 0.001). There were no
significant differences in the net gain (acute gain 2 late loss)
between the stent and the optimal PTCA groups (1.32 6 0.33
vs. 1.24 6 0.29 mm for the stent and optimal PTCA groups,
respectively; p 5 0.42).
Pre-PTCA diameter stenosis was similar in the stent and
the optimal PTCA groups (73.06 6 13% vs. 74.07 6 15%; p 5
NS). Postintervention diameter stenosis was significantly lower
in the stent than in the optimal PTCA group (12.8 6 9% vs.
22.1 6 11%; p 5 0.001). However, at follow-up, angiography
percent residual diameter stenosis was similar for the stent and
the optimal PTCA groups (29.4 6 2.1% vs. 30.3 6 2.1%,
respectively, p 5 0.8).
Angiographic restenosis and clinical follow-up. Follow-up
angiogram was performed at 7.6 6 0.4 months in 112 of 116
(96.6%) patients in the entire group, in 56 of 57 (98.2%)
patients in the stent group and in 56 of 57 (94.9%) in the
PTCA group. As shown in Table 3, angiographic restenosis was
19.2% in the stent and 16.1% in the optimal PTCA group (p 5
0.9). Since the data were analyzed according to intention to
treat, the numbers in the PTCA group included 13.5% of
Figure 1. Cumulative distribution function curves of reference diam-
eter and MLD before, after and at follow-up in the stent group (A) and
in the PTCA group (B). Circle 5 reference diameter; square 5 MLD
post; open triangle 5 MLD pre; solid triangle 5 MLD follow-up.
Table 2. Quantitative Angiographic Data
Stent
(n 5 56)
PTCA
(n 5 56) p
RD (mm) 3.1 6 0.56 2.81 6 0.55 NS
MLD pre (mm) 0.80 6 0.46 0.70 6 0.46 NS
MLD post (mm) 2.7 6 0.59 2.2 6 0.49 5 0.0001
Acute gain (mm) 1.95 1.5 5 0.03
MLD follow-up (mm) 2.1 6 0.9 1.94 6 0.68 NS
Late loss (mm) 0.63 6 0.59 0.26 6 0.44 , 0.001
Net gain (mm) 1.32 6 0.33 1.24 6 0.29
Gain stent/PTCA (mm) 0.08
Percent stenosis
Pre 73.06 6 13 74.07 6 15 NS
Post 12.8 6 9 22.1 6 11 5 0.0001
Follow-up 29.4 6 21 30.3 6 2.1 NS
Abbreviations: MLD 5 minimal luminal diameter; PTCA 5 percutaneous
transluminal coronary angioplasty; RD 5 reference diameter.
Table 3. Six-month Angiographic Restenosis and 1-year Follow-up
Clinical Events for the Stent and Optimal PTCA Groups
Stent PTCA p
Angiographic restenosis (%) 11/56 (19.2) 9/56 (16.1) NS
Death (%) 0/57 (0) 1/59 (1.6) NS
Non–Q-AMI (%) 0/57 (0) 1/59 (1.6) NS
TVR (%) 10/57 (17.5) 8/59 (13.5) NS
CABG (%) 4/57 (6.7) 2/59 (1.7) NS
PTCA/PTCA 1 stent (%) 6/57 (10.5) 6/59 (10.1) NS
Any clinical events (%)* 80.8 83.1 NS
*Included procedural and hospital events. Abbreviations: AMI 5 acute
myocardial infarction; CABG 5 coronary artery bypass graft; PTCA 5 percu-
taneous transluminal coronary artery; TVR 5 target vessel revascularization.
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patients that crossed over to stent at the 30-min angiogram. Of
note, none of these patients had angiographic restenosis at
follow-up.
Late and overall cardiac events and all events are shown in
Table 3. Clinical follow-up data during the first year (range 9 to
23 months) were available for all patients. Target vessel
revascularization was similar in both the stent and the PTCA
group (17.5% vs. 13.5%, respectively p 5 NS). In the optimal
PTCA group, there were both one cardiac death occurring
after CABG surgery and one non–Q-wave myocardial infarc-
tion. There were no deaths or myocardial infarctions in the
stent group. The 1-year event-free survival (freedom from
death, myocardial infarction, angina or new revascularization
procedures) was 80.8% versus 83.1% (p 5 NS) for the stent
and the optimal PTCA groups, respectively (Fig. 2).
Angiographic restenosis and stent design. In the present
study, stent design was not correlated with late outcome. We
used 33 Gianturco Roubin II stents, 28 slotted tube stents (21
Palmaz–Schatz, 2 AVE and 5 Multilinks) and 6 other stents (3
Wiktors and 3 Wallstents). Restenosis was documented in 4 of
33 Gianturco Roubin II stents (12.1%), in 6 of 28 slotted tube
stents (21.4%) and in 1 of 6 other stents (16.6%); p 5 NS. In
other words, restenosis was documented in 4 of the 33 Gian-
turco Roubin II stents (12.1%) and in 7 of the other 34 stents
(20.5%; p 5 NS).
Hospital and follow-up costs. In-hospital costs were US
$502,740 for the stent versus US $331,480 for the optimal
PTCA group (p , 0.03). Optimal PTCA costs included the
13.5% cross over to stent due to early loss in the delayed
angiogram. At follow-up, four patients in stent group under-
went CABG and six a new PTCA (two with stents) for an
additional cost of US $89,000. In the optimal PTCA group, two
patients underwent CABG and six patients a new PTCA, four
with stenting, accounting for US $67,000 additional cost. Thus,
the overall costs for both procedures (hospital and follow-up)
were US $591,740 for the stent and US $398,480 for the
optimal PTCA group (p , 0.02).
Discussion
In this trial we compared two strategies of revascularization
in patients obtaining a good immediate angiographic PTCA
result: elective stent versus a conservative therapy (optimal
PTCA) with a delayed angiogram 30 min after the end of the
procedure to assess changes in MLD. In this latter group,
patients were allowed to cross over to stent only when early
loss in MLD occurred (provisional stenting). The central
finding of the present study is that angiographic restenosis,
TVR and freedom from major combined events at follow-up
were similar in both groups of patients. Furthermore, despite
similar angiographic restenosis and event-free survival at
1-year follow-up, overall costs were significantly higher in the
stent than in the optimal PTCA with provisional stenting
group.
In the present study, the stent strategy resulted in a greater
acute gain than in the optimal PTCA with provisional stenting
approach. However, net gain and angiographic restenosis rates
with both techniques were similar as a result of a significantly
greater late loss in the stent group. These findings are in
agreement with previous studies demonstrating that late loss
due to neointimal proliferation is greater with stents than with
balloon angioplasty (5,6,13,14). Although compared with stent-
ing, optimal PTCA resulted in a smaller post-PTCA MLD, the
smaller late loss occurring after PTCA resulted in a similar net
gain and angiographic restenosis rate at follow-up. Our results
were analyzed according to intention to treat and provisional
stenting was necessary in 13.5% of lesions in the optimal
PTCA group. Since 75% of lesions exhibiting early loss after
successful PTCA develop restenosis (8,9), the restenosis rate
of the PTCA group without provisional stenting would have
been 25 to 30%.
The findings of this trial are in agreement with the hypoth-
esis of lower restenosis rate after balloon angioplasty in those
lesions with no early MLD loss after PTCA (7). As we
previously reported, total loss after successful PTCA has at
least two components: an early loss component detected within
minutes or hours after PTCA and a late component manifested
at 6-month follow-up angiography. Early loss in MLD after
successful PTCA is associated with higher restenosis rates at
follow-up (1,7–9,15–17). A loss in MLD of greater than 0.3 mm
at 24 h after successful PTCA identifies a group of patients
with a 6-month angiographic restenosis rate of 70% (1,9). We
have also demonstrated that coronary stent significantly re-
duces angiographic restenosis in these patients with early loss
of MLD after successful PTCA (9). However, a good initial
PTCA result without early loss in MLD at 24-h follow-up
angiography (“stentlike results”) identified a subgroup of
patients with a low angiographic restenosis rate and a good
long-term outcome (1).
Although the BENESTENT I (5) and STRESS (6) trials
have shown a 30% reduction in late restenosis with the use of
Palmaz–Schatz stents, hospital stays and costs were increased
in these studies. In both trials stent restenosis was similar to the
restenosis rate of the stent group reported in the present study.
Figure 2. One-year event-free survival of patients randomized to stent
or optimal PTCA.
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Our findings of a low restenosis rate and good long-term
outcome in lesions with no early loss in MLD after successful
PTCA are in agreement with those of the BENESTENT I trial,
showing a 16% restenosis rate in lesions with PTCA stentlike
results (18).
In the present study we have a high number of patients with
unstable angina and therefore complex coronary lesion mor-
phology. We have previously demonstrated that early loss in
MLD after successful PTCA occurred in 60% of AHA/ACC
type B and C coronary lesions, and that this angiographic
phenomenon was associated with a high restenosis rate at
follow-up (1). However, it is early loss after successful PTCA
rather than coronary lesion morphology that is the main
determinant of coronary restenosis. No early loss in MLD and
a restenosis rate of 10% occurred in 40% of patients under-
going successful PTCA of type B and C lesions (1). Thus,
regardless of coronary lesion morphology, those lesions with-
out early loss after successful PTCA have a low incidence of
restenosis at follow-up.
Coronary stents have had a dramatic impact in the imme-
diate and long-term outcome of percutaneous revasculariza-
tion procedures. They reduce the incidence of the acute
complications of failed balloon angioplasty and improve sub-
optimal results after PTCA. Furthermore, coronary stents are
the only intervention that has been demonstrated to reduce
both clinical and angiographic restenosis. Coronary stenting
reduces restenosis by achieving a greater acute gain, prevent-
ing the phenomenon of early loss in MLD occurring during the
first 24 h after successful PTCA (8,19,20) and reducing arterial
remodeling. As a result of these beneficial effects, nowadays
stent implantation is used in more than 60% of percutaneous
revascularization procedures. However, compared with con-
ventional balloon angioplasty, coronary stenting has several
potential limitations, including increased cost, a greater degree
of smooth muscle cell proliferation and neointimal formation,
difficult use in some lesion subsets and the increasing problem
of in-stent restenosis. Actually, difficulty in the management of
in-stent restenosis, including the discouraging results of bal-
loon angioplasty due to the high recurrence of restenosis at
follow-up, prompted more patients in the stent group of this
study who developed restenosis to be treated by bypass sur-
gery.
In parallel with the development of the second generation
of percutaneous revascularization devices and adjunctive phar-
macology, the immediate and long-term results of conven-
tional balloon angioplasty have also improved significantly.
This improvement is the result of operator experience, the use
of IIb-IIIa receptor blockers and the availability of coronary
stents to treat acute complications (abrupt and threatening
occlusion) and suboptimal results of conventional balloon
angioplasty. Thus, nowadays a more aggressive conventional
balloon angioplasty can be performed as the predominant
technique of percutaneous coronary revascularization with a
provisional stenting strategy for the treatment of abrupt and
threatening occlusion or suboptimal results. In fact, a lower
target lesion revascularization was achieved in the PTCA arm
of the BENESTENT II, BOAT and EPILOG trials. In those
studies, similar to the present study, the PTCA strategy
required 14% provisional stenting. These findings provide
preliminary evidence that a strategy of aggressive conventional
balloon angioplasty with the limited use of provisional stenting
to treat angioplasty complications or suboptimal results may be
highly effective. Our pilot study provides the basis for larger
randomized trials to compare the strategy of universal stenting
with one of optimal angioplasty with provisional stenting.
A coronary intervention strategy including a delayed coro-
nary angiogram 30 min after a good immediate angiographic
result of PTCA allowing crossover to provisional stenting only
if early loss occurs adds additional cost and decreases the
efficiency of the interventional procedure. Since in the
DEBATE trial an impaired post-PTCA coronary flow reserve
predicted subsequent clinical events (21), it is possible that
intracoronary Doppler would allow early identification and
stenting of coronary lesions prone to experience early loss in
MLD after successful PTCA.
Study limitations. We recognize certain limitations of this
study. First, our sample size was small and it is possible that a
type 2 error could have occurred in this equivalency trial.
Therefore larger randomized studies are necessary to address
definite conclusions. Furthermore, although there were no
statistically significant differences in baseline characteristics
between the two groups, there were some important differ-
ences, including a higher incidence of left anterior descending
lesions in the stent group and an incidence of diabetes in the
PTCA group that was twice that of the stent group.
Second, the estimated cost of interventional procedures in
the study was analyzed on the basis of their costs in the
countries involved in the OCBAS trial, and would be different
if the PTCA and stents procedures had been performed in the
United States or Europe. However, the costs were calculated
following the criteria of the National Social Security System of
Argentina, Chile and Uruguay. Third, a heterogeneity of stent
designs was used in this study, including a large percentage of
Gianturco Roubin II stents. Although the multicenter study
comparing the Gianturco Roubin II versus Palmaz–Schatz
appears to show a lower restenosis rate in the Palmaz group,
these results are controversial (22). Our study demonstrated a
lack of correlation between angiographic restenosis, late out-
come and stent design. Restenosis was documented in 12.1%
of the Gianturco Roubin II stents versus 20.5% of the remain-
ing stent designs (p 5 NS). These findings are in agreement
with those of the FRESCO and the GRAMI trials (23,24),
demonstrating low target lesion revascularization after Gian-
turco Roubin II stent implantation.
Conclusions. Compared with coronary stenting, a strategy
of optimal PTCA with provisional stenting resulted in similar
angiographic restenosis rates, TVR and freedom from major
combined events at 1 year of follow-up. Furthermore, the
overall cost of the stent strategy was significantly higher.
A delayed angiogram after a good immediate angiographic
result of PTCA identifies a group of patients with good
long-term outcome, allowing to crossover to provisional stent
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only if early loss in MLD occurs. Therefore, stenting after
successful PTCA should be avoided if early loss in MLD is not
present.
Optimal Coronary Balloon Angioplasty with Provisional Stenting vs. Stent
(OCBAS)
Study Organization and participants:
Coordinating Center: Centro de Estudios en Cardiologia Intervencionista
(CECI). Alfredo Rodrı´guez, MD, PhD, Buenos Aires, Argentina; Igor F.
Palacios, MD, Massachusetts General Hospital, Harvard Medical School, Bos-
ton, MA.
Participating Centers:
Sanatorio Otamendi: Alfredo Rodrı´guez, MD, PhD; Carlos Mauvecin, MD;
Victor Bernardi, MD; Jorge Martı´nez; Pablo Boskis, Buenos Aires, Argentina.
Sanatorio Anchorena: Alfredo Rodrı´guez, MD, PhD; Omar Santaera, MD;
Mario Ferna´ndez, MD, Buenos Aires, Argentina.
Hospital Espan˜ol: Alfredo Rodrı´guez, MD, PhD; Alberto Cristino, MD;
Daniel Vogel, MD, Bahı´a Blanca, Argentina.
Clı´nica Belgrano: Omar Santaera, MD; Alejandro Dellacasa, MD, Mar del
Plata, Argentina.
Universidad Nacional de Chile: Francisco Ayala, MD; Gasto´n Dussallian,
MD, Santiago de Chile, Chile.
Universidad Cato´lica de Chile: Eugenio Marchand, MD; Alejandro Martı´nez,
MD, Santiago de Chile, Chile.
Hospital Militar de Chile: Rene Pumatino, MD; Oscar Novoa, MD, Santiago
de Chile, Chile.
Instituto de Cirugı´a Cardı´aca: Ce´sar Pardin˜as, MD, Montevideo, Uruguay.
Central Core Laboratory: Igor F. Palacios, MD, Lari C. Harrell, BS, Massa-
chusetts General Hospital, Harvard University, Boston, MA.
Safety and Data Monitoring Committee: Ramo´n Corbalan, MD, Santiago,
Chile; Ne´stor Pe´rez Balin˜o, MD, Buenos Aires, Argentina.
Statistics: Ulises Questa, MD, PhD, Buenos Aires, Argentina; Lari C. Harrell,
BS, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
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